Melanocytic Neoplasm

The researchers quantified ctDNA in time-intervals during the treatment of 6 patients with stage IV melanoma. The patient carrying the NRAS Q61H mutation was started on ipilimumab and responded well. … (full text at CIViC)

PMID 26095797 · Tsao et al., 2015 · Open in CIViC

Established a novel mouse model for melanoma that shows for the first time that over expression of a mutant form of human N-ras (N-RasQ61K) in melanocytes results in a hyper pigmented skin phenotype a… (full text at CIViC)

PMID 15899789 · Ackermann et al., 2005 · Open in CIViC

Recent studies in mouse have also shown that NRAS Q61K is capable of promoting melanoma formation and cooperates with INK4A loss to accelerate tumor onset.

PMID 19954345 · Dovey et al., 2009 · Open in CIViC

Two patients with NRAS Q61K-mutant melanoma treated with belvarafenib had progressive disease as their best RECIST response. One patient progressed after 1.6 months and the other after 1.4 months of t…

A patient with mucosal melanoma harboring NRAS Q61L received belvarafenib monotherapy after five prior lines of systemic therapy and achieved a confirmed partial response by RECIST. The patient receiv… (full text at CIViC)

PMID 38470950 · Kim et al., 2024 · Open in CIViC

In the NRAS Q61L-mutant IPC-298 melanoma model, NST-628 inhibited cell viability and induced apoptosis in vitro. In IPC-298 xenografts, NST-628 at 5 mg/kg once daily or 1.5 mg/kg twice daily produced … (full text at CIViC)

PMID 38588399 · Ryan et al., 2024 · Open in CIViC

A patient with cutaneous melanoma harboring NRAS Q61R received belvarafenib monotherapy after two prior lines of systemic therapy and had progressive disease as the best RECIST response. The patient r… (full text at CIViC)

PMID 38470950 · Kim et al., 2024 · Open in CIViC

A patient with melanoma harboring NRAS Q61R received belvarafenib monotherapy after one prior line of systemic therapy and achieved stable disease as the best RECIST response. At the October 2023 data… (full text at CIViC)

PMID 38470950 · Kim et al., 2024 · Open in CIViC

A 4 year old African American girl was seen for a lesion on the scalp. Punch biopsy was done on a largely skin-colored subcutaneous nodule. Subcutaneous nodular aggregations of heavily pigmented epith… (full text at CIViC)

PMID 31437301 · Friedman et al., 2020 · Open in CIViC

BRAF-fusion in "pan-negative" melanomas were identified in TCGA data. Cell-lines with a PAPSS1-BRAF fusion were resistant to treatment with Vemurafenib but sensitive to treatment with Trametinib. This… (full text at CIViC)

PMID 24345920 · Hutchinson et al., 2013 · Open in CIViC

BRAF-fusion in "pan-negative" melanomas were identified in TCGA data. Cell-lines with PAPSS1-BRAF fusion were resistant to treatment with Vemurafenib.

PMID 24345920 · Hutchinson et al., 2013 · Open in CIViC

PDGFRA mutations (exon 12, 14, 18) were assessed in 351 melanoma patient samples. 18 different mutations were detected in 4,6% of samples (all without chronic sun-induced damage and mainly in acral an… (full text at CIViC)

PMID 24132921 · Dai et al., 2013 · Open in CIViC

PDGFRA mutations (exon 12, 14, 18) were assessed in 351 melanoma patient samples. 18 different mutations were detected in 4,6% of samples (all without chronic sun-induced damage and mainly in acral an… (full text at CIViC)

PMID 24132921 · Dai et al., 2013 · Open in CIViC

PDGFRA mutations (exon 12, 14, 18) were assessed in 351 melanoma patient samples. 18 different mutations were detected in 4,6% of samples (all without chronic sun-induced damage and mainly in acral an… (full text at CIViC)

PMID 24132921 · Dai et al., 2013 · Open in CIViC

PDGFRA mutations (exon 12, 14, 18) were assessed in 351 melanoma patient samples. 18 different mutations were detected in 4.6% of samples (all without chronic sun-induced damage and mainly in acral an… (full text at CIViC)

PMID 24132921 · Dai et al., 2013 · Open in CIViC

PDGFRA mutations (exon 12, 14, 18) were assessed in 351 melanoma patient samples. 18 different mutations were detected in 4.6% of samples (all without chronic sun-induced damage and mainly in acral an… (full text at CIViC)

PMID 24132921 · Dai et al., 2013 · Open in CIViC

PDGFRA mutations (exon 12, 14, 18) were assessed in 351 melanoma patient samples. 18 different mutations were detected in 4.6% of samples (all without chronic sun-induced damage and mainly in acral an… (full text at CIViC)

PMID 24132921 · Dai et al., 2013 · Open in CIViC

An in vitro study of M229 (a human melanoma cell line) endogenously expressing wildtype PIK3CA and BRAF V600E (a known BRAF inhibitor sensitizing mutation) found that cells virally induced to stably o… (full text at CIViC)

PMID 24265155 · Shi et al., 2014 · Open in CIViC

An in vitro study of M229 (a human melanoma cell line) endogenously expressing wildtype PIK3CA and BRAF V600E (a known BRAF inhibitor sensitizing mutation) found that cells virally induced to stably o… (full text at CIViC)

PMID 24265155 · Shi et al., 2014 · Open in CIViC

An in vitro study of M229 (a human melanoma cell line) endogenously expressing wildtype PIK3CA and BRAF V600E (a known BRAF inhibitor sensitizing mutation) used PIK3CA E545K as a positive control for … (full text at CIViC)

PMID 24265155 · Shi et al., 2014 · Open in CIViC

An in vitro study of M229 (a human melanoma cell line) endogenously expressing wildtype PIK3CA and BRAF V600E (a known BRAF inhibitor sensitizing mutation) found that cells induced to stably over-expr… (full text at CIViC)

PMID 24265155 · Shi et al., 2014 · Open in CIViC

An in vitro study of WM2664 (a human melanoma cell line) endogenously expressing wildtype PIK3R2 and BRAF V600D (a known BRAF inhibitor sensitizing mutation) found that cells induced to stably over-ex… (full text at CIViC)

PMID 24265155 · Shi et al., 2014 · Open in CIViC

Case report of a 47year old female patient with metastatic melanoma (BRAF, NRAS, KIT negative). A PPFIBP2-BRAF fusion was identified from DNA from a brain metastasis (inton 3 of PPFIBP2 fused to intro… (full text at CIViC)

PMID 26072686 · Menzies et al., 2015 · Open in CIViC

In a retrospective analysis of the Allen cohort of 110 patients with advanced melanoma treated with CTLA-4 blockade, 9 patients with nonsynonymous PRKDC mutations had a higher objective response rate … (full text at CIViC)

PMID 32502294 · Chen et al., 2020 · Open in CIViC

A 26-year old patient presented with vemurafenib resistant BRAF V600E-mutated cutaneous melanoma. Five metastases were evaluated using whole genome sequencing and a 4-bp deletion in PTEN (frameshift m… (full text at CIViC)

PMID 24504448 · Turajlic et al., 2014 · Open in CIViC

An in vitro study of WM2664, a PTEN non-expressing and BRAF V600E mutated human melanoma cell line, associated PTEN expression with sensitivity to vemurafenib, as measured by cell survival. When treat… (full text at CIViC)

PMID 24265155 · Shi et al., 2014 · Open in CIViC

In vitro and in vivo studies that demonstrate that RAC1-P29S is capable of promoting cell survival and resistance to treatment, specifically BRAF inhibition. The authors expressed both a 4-hydroxytamo… (full text at CIViC)

PMID 31257073 · Lionarons et al., 2019 · Open in CIViC

In a retrospective study, resistance mechanisms to BRAF inhibitor such as vemurafenib or dabrafenib in patients with BRAF V600 mutated melanoma were evaluated. Among the 14 patients exhibiting early d… (full text at CIViC)

PMID 24265153 · Van Allen et al., 2014 · Open in CIViC

Retrospective analysis of somatic mutations and copy number changes in 119 patients treated with carboplatin, paclitaxel, ± sorafenib (CPS) in the E2603 trial. CPS therapy was associated with improved… (full text at CIViC)

PMID 26307133 · Wilson et al., 2016 · Open in CIViC

In an in vitro study, M375 and M238 cell lines expressing RAF1 (CRAF) R391W demonstrated resistant to vemurafenib treatment compared to M397 cells expressing BRAF V600E (a known vemurafenib sensitizin… (full text at CIViC)

PMID 27273450 · Atefi et al., 2016 · Open in CIViC

A 51 year old male patient with metastatic cutaneous melanoma harboring a RUFY1::RAF1 fusion received the MEK inhibitor binimetinib after prior pembrolizumab and ipilimumab/nivolumab. During four mont… (full text at CIViC)

PMID 35871080 · Moran et al., 2022 · Open in CIViC

FACS-assisted shRNA genetic screen identified SOX10 as a determinant of vemurafenib resistance. Suppression of SOX10 in melanoma cells confers resistance to BRAF and MEK inhibitors through activation … (full text at CIViC)

PMID 24670642 · Sun et al., 2014 · Open in CIViC

A375 melanoma cells containing an inducible shRNA for STAG2 were grown as xenograft tumors in nude mice. The mice in which STAG2 was silenced had tumors that were less sensitive to vemurafenib-induced… (full text at CIViC)

PMID 27500726 · Shen et al., 2016 · Open in CIViC